OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Showing 24 citing articles:
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 39
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 39
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
Bains Jasleen, Gupta K Vishal, Malepati Sameera, et al.
Cureus (2023)
Open Access | Times Cited: 37
Bains Jasleen, Gupta K Vishal, Malepati Sameera, et al.
Cureus (2023)
Open Access | Times Cited: 37
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Hae‐Kyung Kim, Geert Jan Biessels, Min Yu, et al.
Neurology (2024) Vol. 103, Iss. 8
Closed Access | Times Cited: 15
Hae‐Kyung Kim, Geert Jan Biessels, Min Yu, et al.
Neurology (2024) Vol. 103, Iss. 8
Closed Access | Times Cited: 15
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Advancing the understanding of diabetic encephalopathy through unravelling pathogenesis and exploring future treatment perspectives
Aarti Nagayach, Rakesh Bhaskar, Shampa Ghosh, et al.
Ageing Research Reviews (2024) Vol. 100, pp. 102450-102450
Closed Access | Times Cited: 6
Aarti Nagayach, Rakesh Bhaskar, Shampa Ghosh, et al.
Ageing Research Reviews (2024) Vol. 100, pp. 102450-102450
Closed Access | Times Cited: 6
SGLT inhibitors for improving Healthspan and lifespan
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 15
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 15
Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
Maaly A. Abd Elmaaboud, Remon S. Estfanous, Aliaa Atef, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1370-1370
Open Access | Times Cited: 13
Maaly A. Abd Elmaaboud, Remon S. Estfanous, Aliaa Atef, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1370-1370
Open Access | Times Cited: 13
Canagliflozin attenuates chronic unpredictable mild stress induced neuroinflammation via modulating AMPK/mTOR autophagic signaling
Lobna H. Khedr, Reem M Eladawy, Noha N. Nassar, et al.
Neuropharmacology (2022) Vol. 223, pp. 109293-109293
Closed Access | Times Cited: 21
Lobna H. Khedr, Reem M Eladawy, Noha N. Nassar, et al.
Neuropharmacology (2022) Vol. 223, pp. 109293-109293
Closed Access | Times Cited: 21
Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes
Giuseppe Lisco, Anna De Tullio, Michele Iovino, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2993-2993
Open Access | Times Cited: 11
Giuseppe Lisco, Anna De Tullio, Michele Iovino, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2993-2993
Open Access | Times Cited: 11
Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer’s disease in type 2 diabetes
Prakash Ramakrishan, Jayaraman Rajangam, Shaheedha Shabudeen Mahinoor, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 3
Closed Access
Prakash Ramakrishan, Jayaraman Rajangam, Shaheedha Shabudeen Mahinoor, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 3
Closed Access
Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: A propensity-matched retrospective cohort study
Pei-Chun Chiang, Cheng-Yang Hsieh, Sheng‐Feng Sung
Journal of Stroke and Cerebrovascular Diseases (2025), pp. 108276-108276
Open Access
Pei-Chun Chiang, Cheng-Yang Hsieh, Sheng‐Feng Sung
Journal of Stroke and Cerebrovascular Diseases (2025), pp. 108276-108276
Open Access
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 11, pp. 465-465
Open Access | Times Cited: 9
Michail Koutentakis, Jakub Kuciński, Damian Świeczkowski, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 11, pp. 465-465
Open Access | Times Cited: 9
Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
Veera Ganesh Yerra, Kim A. Connelly
Physiology (2024) Vol. 39, Iss. 6, pp. 412-434
Closed Access | Times Cited: 1
Veera Ganesh Yerra, Kim A. Connelly
Physiology (2024) Vol. 39, Iss. 6, pp. 412-434
Closed Access | Times Cited: 1
Could the administration of SGLT2i agents serve as a viable prophylactic approach against CNI-induced toxicities?
Emad Molaei, Ali Molaei, Simin Dashti‐Khavidaki, et al.
Medical Hypotheses (2024) Vol. 189, pp. 111417-111417
Closed Access | Times Cited: 1
Emad Molaei, Ali Molaei, Simin Dashti‐Khavidaki, et al.
Medical Hypotheses (2024) Vol. 189, pp. 111417-111417
Closed Access | Times Cited: 1
Empagliflozin Dampens Doxorubicin-Induced Chemobrain in Rats: The Possible Involvement of Oxidative Stress and PI3K/Akt/mTOR/NF-κB/TNF-α Signaling Pathways
Rania M. Abdelsalam, Hatem W Hamam, Noha M Eissa, et al.
Molecular Neurobiology (2024)
Closed Access | Times Cited: 1
Rania M. Abdelsalam, Hatem W Hamam, Noha M Eissa, et al.
Molecular Neurobiology (2024)
Closed Access | Times Cited: 1
Sodium-Glucose Cotransporter-2 Inhibitors in Depression
David T. Liebers, Wataru Ebina, Dan V. Iosifescu
Harvard Review of Psychiatry (2023) Vol. 31, Iss. 4, pp. 214-221
Closed Access | Times Cited: 3
David T. Liebers, Wataru Ebina, Dan V. Iosifescu
Harvard Review of Psychiatry (2023) Vol. 31, Iss. 4, pp. 214-221
Closed Access | Times Cited: 3
Impact of SGLT2 Inhibitors on Corneal Nerve Morphology and Dendritic Cell Density in Type 2 Diabetes
Kofi Asiedu, Shyam Sunder Tummanapalli, Sultan Alotaibi, et al.
Ocular Immunology and Inflammation (2023) Vol. 32, Iss. 2, pp. 234-241
Closed Access | Times Cited: 2
Kofi Asiedu, Shyam Sunder Tummanapalli, Sultan Alotaibi, et al.
Ocular Immunology and Inflammation (2023) Vol. 32, Iss. 2, pp. 234-241
Closed Access | Times Cited: 2
Increased serum SGLT2 and its potential diagnostic and prognostic value in patients with acute ischemic stroke
Yuhan Dong, Bo Long, Zhanglin Tian, et al.
Clinical Biochemistry (2024) Vol. 125, pp. 110733-110733
Closed Access
Yuhan Dong, Bo Long, Zhanglin Tian, et al.
Clinical Biochemistry (2024) Vol. 125, pp. 110733-110733
Closed Access
Empagliflozin modulates seizure activity and oxidative stress in rats with epilepsy
Neha Holla, Shalini Adiga, Meena Kumari, et al.
Journal of Cellular Neuroscience and Oxidative Stress (2024) Vol. 16, Iss. 2, pp. 1195-1204
Open Access
Neha Holla, Shalini Adiga, Meena Kumari, et al.
Journal of Cellular Neuroscience and Oxidative Stress (2024) Vol. 16, Iss. 2, pp. 1195-1204
Open Access
Re-purposing SGLT-2 inhibitors for diabetic striatopathy
Subhankar Chatterjee, Ritwik Ghosh, Souvik Dubey, et al.
Primary care diabetes (2024)
Closed Access
Subhankar Chatterjee, Ritwik Ghosh, Souvik Dubey, et al.
Primary care diabetes (2024)
Closed Access
Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer’s Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling
Hemat A. Elariny, Ahmed M. Kabel, Heba Mohammed Refat M. Selim, et al.
Medicina (2024) Vol. 60, Iss. 11, pp. 1805-1805
Open Access
Hemat A. Elariny, Ahmed M. Kabel, Heba Mohammed Refat M. Selim, et al.
Medicina (2024) Vol. 60, Iss. 11, pp. 1805-1805
Open Access
